Companies Dominating the Meloxicam Landscape
- Taj Pharmaceutical Limited.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Wellona Pharma
- Trumac Healthcare
- Healthy Life Pharma Private Limited.
- EPICON LIFESCIENCES LLP
- Boehringer Ingelheim GmbH.
- Baudax Bio
- Heron Therapeutics Inc.
- Avanstra Inc.
- PD-Rx Pharmaceuticals, Inc.
Browse Key Market Insights with Data Illustration:
In the News
- Baudax Bio, Inc., a pharmaceutical company specializing in acute care therapies, announced that ANJESO (meloxicam), the only 24-hour intravenous COX-2 preferred nonsteroidal anti-inflammatory drug , is now available at command. and deliver goods to customers. ANJESO was approved by the U.S. Food and Drug Administration (FDA) on February 20, 2020, and is indicated for the treatment of moderate to severe pain, alone or in combination with other medications. Other non-NSAID pain relievers.
- Heron Therapeutics, Inc., a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important needs of patients, today announced that the U.S. Food and Drug Administration (FDA) has approved ZYNRELEF (bupivacaine and meloxicam) extended-release solution for use in adults to soft tissue or periarticular drops to provide postoperative analgesia for up to 72 hours after bunionectomy, open inguinal hernia, and total knee replacement surgery.
